Escugen and Hua Huian kin (Beijing) Biotechnology Co., Ltd. join hands to reach a global strategic cooperation on next-generation targeted ADC drugs

EscugenHealth BiologicsTechnologyCo., Ltd. ("Escugen" and Hua Huian kin (Beijing) Biotechnology Co., Ltd. ("Hua Huian kin") jointly announced that they have reached an exclusive global cooperation development agreement for an undisclosed novel cancer target, and will jointly research and develop a potential "First-in-Class” ADCCandidate Drug。

This collaboration will fully leverage Escugen's independently developedEZWi-Fit® ADC Platform Technical Advantages, Combined with Hua Huian kin (Beijing) Biotechnology Co., Ltd.High tumor-specific fully human antibody development capability, achieving organic integration of technology and innovation, making this cooperationADCDrugs with Greater Market Competitiveness and Innovative ValueAccording to the plan, both parties will jointly promote thisADC drugs have entered the clinical stage, with target indications covering multiple solid tumor fields with unmet clinical needs.

Escugen Founder andDr. Zhou Qing, CEO, stated: "Relying on the excellent antibody engineering technology of Hua Huian kin (Beijing) Biotechnology Co., Ltd., this target has shown significant potential. Combined with Escugen's...Multiple preclinical andClinicalProjectValidatedEZWi-Fit® platform, we are hopeful to jointly push this candidate drug to new heights, broaden its therapeutic window, and enhance its resistance threshold.。”

Hua Huian kinCEO Dr. Chen Bin said: "EscugenEZWi-Fit® Technology Platform Clinically Validated，This collaboration involves Hua Huian kin (Beijing) Biotechnology Co., Ltd.'s newly engineered antibody targeting a novel site, jointly developed by both parties.First-in-Class ADC Candidate Drug with the Potential to Demonstrate Clinical Advantages Beyond Existing Therapies。”

Hua Huian kin(Beijing)Biotechnology Co., Ltd. was foundedIn 2015,Is a biotechnology company in the clinical stage,Dedicated to Developing Innovative Therapies for Liver Diseases and Cancer, FocusChronic Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV) Infection,These two in fullA highly harmful and widely prevalent infectious disease on a global scale.With our deep accumulation in the fields of disease biology and protein engineering, the company has established a pipeline containing multiple"First-in-class" and "Best-in-class" candidate drug development pipelines.With"Truth and Innovation" as the core values, enabling innovative products from China to benefit patients worldwide.

Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on innovation.Development of ADC Drugs. Escugen's leading Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen’s next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, resistance prevention, and pharmacokinetic properties. Leveraging this platform technology, Escugen is rapidly expanding its ADC product line targeting novel or validated targets. The first ADC product incorporating EZWi-Fit® technology has successfully initiated its first-in-human clinical trial. Escugen has also successfully licensed this platform technology to several domestic and international biotechnology companies, empowering their innovative ADC projects.